Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Recruiting
N/A
Interventional Study
Myeloid Malignancy
Inherited Bone Marrow Failure Syndrome
Clonal Expansion
Cytopenia
Bone Marrow Failure Syndrome
Clonal Cytopenia of Undetermined Significance
Clonal Hematopoiesis of Indeterminate Potential
Hematologic Neoplasms
Hematopoietic and Lymphatic System Neoplasm
Hereditary Neoplastic Syndrome
Idiopathic Cytopenia of Undetermined Significance
Idiopathic Dysplasia of Uncertain Significance
Low Risk Myelodysplastic Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 2,000 (estimated)
- Sponsor
- Mayo Clinic · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and le…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with idiopathic cytopenias of unclear significance (ICUS)
* Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \[CHIP\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin…
Contacts